Newswise — You thought Alzheimer’s was complicated? Or Parkinson’s? Try dementia with Lewy bodies, the disease occupying the awkward territory between those two poles. DLB is arguably the second-most-common form of dementia, but it is heterogeneous and often overlooked. Yet the International Dementia with Lewy Bodies Conference held earlier this month in Fort Lauderdale, Florida, showcased a field coming into its own. For four days, 400 researchers, patients, care partners, and other stakeholders traded new insights. Because this conference last convened about a decade ago, there was much to learn. Over the din of disease classification debates that perennially accompany spectrum diseases, the meeting reflected a field trying to build on a broadly accepted consensus diagnosis, its unifying foundation. Pharmaceutical companies are dipping in their toes, brain imaging is making it possible to see what’s going on in the brain, GWAS are ramping up, and prodromal biomarker cohorts are forming. Farthest ahead is Japan—the only country that has annual DLB conferences, an approved medication, as well as arguably the best diagnostic scan standardized across centers. Read Alzforum’s six-part daily news series about DLB, starting today.
About UsFounded in 1996, Alzforum is a news and information resource website dedicated to helping researchers accelerate discovery and advance development of diagnostics and treatments for Alzheimer’s disease and related disorders.
Our site expands the traditional mode of scientific communication by reporting the latest scientific findings and industry news with insightful analysis that puts breaking news into context. We advance research by developing open-access databases of curated, highly specific scientific content to visualize and facilitate the exploration of complex data. Alzforum is a platform to disseminate the evolving knowledge around basic, translational, and clinical research in the field of AD.
Alzforum is supported by a team with backgrounds in science, journalism, information technology, design, and data science. Together with a distinguished Scientific Advisory Board, and the active participation of a global network of scientists, we strive to produce unbiased content to a rigorous editorial standard.
Alzforum is operated by the Biomedical Research Forum (BRF) LLC. BRF is a wholly owned subsidiary of FMR LLC. FMR LLC and its affiliates invest broadly in many companies, including life sciences and pharmaceutical companies.Alzforum does not endorse any specific product or scientific approach.
RSS